THE GLOBAL CLINICAL TRIALS SOFTWARE MARKET SIZE WAS VALUED AT USD 930.22 MILLION IN 2021 AND IS EXPECTED TO REACH USD 2.1 BILLION BY 2027, GROWING AT A CAGR OF 15.35% DURING THE FORECAST PERIOD.

The Global Clinical Trials Software Market Size, Share, Trends Analysis by

  • Deployment: On-enterprises, On-Site
  • Delivery: Web-based, SaaS, On-Premises
  • Feature: EDC, eCOA/ePRO, eConsent
  • End-User: CROs, Bio-Pharmaceutical Companies, Medical Device Manufacturer, Others

Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022–2027

Licence Types What are these?
GET ACTIONABLE INSIGHTS ON HOW COVID-19 IS IMPACTING YOUR BUSINESS
Enquire Now Download Free Sample

Most Exhaustive Report

icon-pages

275 Pages

icon-table

130 Tables

icon-chart

133 Charts

icon-region

5 Regions

icon-country

18 Countries

icon-company

27 Companies

icon-market

5 Market Segment

GLOBAL CLINICAL TRIALS SOFTWARE MARKET REPORT SCOPE

Report Attribute Details
Market Size (2027) USD 2.1 Billion
Market Size (2021) USD 930 Million
CAGR (2022-2027) 15%
Base Year 2021
Forecast Year 2022-2027
Market Segments Deployment (On-enterprises, On-Site), Delivery (Web-based, SaaS, On-Premises), Feature(EDC, eCOA/ePRO, eConsent), End-User (CROs, Bio-Pharmaceutical Companies, Medical Device Manufacturer, Others)
Key Vendors BSI, Clario, Dassault Systemes, IQVIA, Labcorp Drug Development, Oracle, Paraxel

MARKET INSIGHTS

The clinical trials software market is expected to grow at a CAGR of 15.35% from 2022 to 2027 and is projected to reach $ 2.1 billion by 2027 from $930.22 million in 2021. Clinical trials play an essential role in discovering new treatments for diseases and better ways to detect diseases, diagnose, and prevent the chance of developing the disease. The clinical trial process indicates what works for humans and what doesn't by testing them on humans in a professional setup. The clinical trials software market growth is due to the increasing demand from pharmaceutical organizations to minimize the cost of medical research, reduce the burden, and increase access to advanced technologies.

Clinical trial software is also known as a clinical trial management system (CTMS). The software is used to manage research activities by the contract research organization (CROs). Increasing clinical trials worldwide drive the demand for new standard software solutions that enable easy access to activities for sponsors, CROs, medical device manufacturers, and outsourcing organizations engaged in medical research activities.

In global biopharmaceutical industries, there are significant changes addressed in the last decades, such as externalizing drugs research and development activities and manufacturing with the help of crucial strategies such as a partnership with small-medium size biopharma companies, academic institutes, government research institutes, and centers, etc. As a part of the significant changes in those industries, CROs became essential to clinical trial services. It helps speed up drug development processes and increase the manufacturing capabilities per the market's needs. But the introduction of CTMS solved several challenges. It allowed the CROs and sponsors to overcome the restraint burden in clinical trials, from drug discovery to clinical trial phases and the approval cycle of drugs.

Recently, the COVID-19 crisis increased the digitalization of medical trials, and the adoption of digital tools and remote monitoring devices in the virtual clinical trial process has risen sharply. High focus on R&D activities, increasing demand for specialty medicines, and real-world evidence are some factors that led to the adoption of clinical trial management software solutions.

Remote clinical trial monitoring is the new standard for performing research in recent times. Clinical trials are a highly complex and expensive, and time-consuming process. So, with the increasing burden of medical research activities, most biopharma companies complete clinical trials with their in-house capabilities or by contract research organizations. So, vendors are adopting remote monitoring software due to the growing security purpose, well-established protocol, and ensuring that the research site conducts the clinical trials as per the protocol.

The COVID-19 pandemic has accelerated the ongoing shift toward remote monitoring through clinical trial management software solutions. It is one of the essential elements in the medical practice and is one of the most critical connections between CROs, sponsors, and the research site.

Cloud computing is a rapidly growing concept leveraging opportunities for market vendors. The shift from traditional methods such as paperwork to complete electronic tool applications will provide lucrative opportunities for market growth. The electronic data capture, transcribing data, Smart devices, and wearable solutions help directly collect data from patients without visiting the trial site. It helps collect data faster without disturbing patients' daily life activities. It helps in the retention of patients. It reduced transportation and travel cost. Conversely, the growing craze for virtual research activities among the biopharma and medical device organizations will drive the demand for Clinical trials management software.

Due to insufficient recruitment and retention of participants in the study population, more than 80% of the research is failing, getting extended, and adding new study sites. Virtual clinical trials are witnessing growth due to increased patient enrolment through software solutions.  In contrast, virtual patient recruitment software allows recruiting patients from across the globe, fulfills the demand, and increases the chances of success. It helps to eliminate the frequent traveling to study sites and do automation in medical data collection, increasing patient engagement and retention.

Virtual collaboration strategies in medical research, using clinical trials management software, allow businesses to work rapidly and more efficiently, eliminate the need for document sharing to additional office locations, and reduce the burden.

Key players prefer the usage of unified platforms for conducting medical research. This provides multiple features that companies can use to conduct research. Medidata, a large clinical trials software provider, has one of the most robust unified platforms most customers use. 

As per the Clinical Trials Arena article in 2022, IQVIA is one of the leading pharma companies in cloud computing. It shows that the filing of the companies in the pharmaceutical industry increased by 12% between Q2 to Q3 in 2021.

One of the factors driving the market growth is the increasing complexity of clinical trial processes. Stringent regulation, the longer lifecycle of research, and the high cost significantly increased the adoption of digital tools in tests to reduce the cost and timeline challenges.

During the COVID-19 pandemic, most biopharma companies rapidly turned toward vaccine production. As well as running clinical trials were conducted using software solutions like remote monitoring and more.

MARKET SEGMENTATION

The market is segmented into on-enterprises and on-site segments. In 2021, the on-enterprises segment accounted for 78.75% market share and dominated the deployment segment. Due to increasing technology adoption in biopharmaceutical companies and rising clinical trial management systems usage, on-enterprises deployment is in higher demand. On-site deployment offers numerous advantages to contracting research organizations, sponsors, and academic and government institutes looking for new drug development. Biopharmaceutical companies have their own IT infrastructure, which helps them easily handle the CTMS solution for their research activities and reduces the cost and timeline in patient data management, documentation, and scheduling of tasks. It is a one-time investment for organizations that delivers long-life services.

In 2021, the web-based delivery segment dominated the market with a 44.79% market share. Major biopharmaceuticals use web-based delivery. Web-based software instantly changes the current landscape, such as data management, statistical analysis, medical writing, and regulatory submission. Their reviews are quickly done by the web-based clinical trials management software delivery methods. Increasing competitiveness in biopharma and contract research companies demands technology adoption and propelling the growth of software adoption. So, the delivery method through the web reduces the data entry and confusion between a broad range of data and helps direct data collection from participants through internet platforms. SaaS solutions have a lot of benefits that influence market growth. The rising acceptance of SaaS- (Software as a service) in CTMS is helping in faster delivery.

The global clinical trials software market is segmented into EDC, eCOA/ePRO, and eConsent. EDC is also referred to as electronic case report form (eCRF), which is vital software. Due to increasing medical research studies worldwide, data accuracy is becoming more critical. EDC is used to collect patient data and analyze the data produced during medical research studies. Increasing demand for patient participants and the rising use of EDC for data capturing drive the growth of the global clinical trials management system market. EDC dominated the global market with a  share of 46.32% in 2021.

In 2021, CROs accounted for 45.95% of the clinical trials management system market share. The CRO organization experienced significant medical research demands from biopharmaceutical companies, medical device manufacturers, and other medical research authorities. Increasing competition in research development by biotech and pharmaceutical companies, high capital investment, and low success rate of clinical trials are some factors driving the demand for CROs.

North America is the leading clinical trials software market, with a market share of 34.03% in 2021. North America's clinical trials management system market was valued at USD 316.55 million in 2021. In North America, the presence of market players, a high number of biopharma companies, and research and development expenditure are the major factors propelling the market growth in the North American region.

COMPETITION ANALYSIS

Increasing collaboration, rising adoption of cloud-based platforms, and new solution availabilities are factors that influence the high competition in the global clinical trial software market. Many regional clinical trial software companies also invest in the latest software products in Europe, APAC, and North America. Regional and local companies threaten global players due to their innovative and cost-effective products and technologies. This indicates that the market offers tremendous growth opportunities for existing and emerging players.

Every year number of new market players enter the market, which will positively influence the competition in the market.

Key Vendors

  • BSI Business Systems Integration
  • Clario
  • Dassault Systemes
  • IQVIA
  • Labcorp Drug Development
  • Oracle
  • Paraxel

Frequently Asked Questions

What was the global clinical trials management software market value in 2021?

The global clinical trials software market was valued at USD 930.22 million in 2021 and is expected to reach USD 2.1 billion by 2027.

How big is the clinical trials management system market?

The global clinical trials software market revenue will hit USD 2.1 billion by 2027.

Who are the key vendors in the clinical trials management systems market?

BSI, Clario, Dassault Systemes, IQVIA, Labcorp Drug Development, Oracle, Paraxel

What are the factors driving the clinical trials management software market growth?

Cloud computing in clinical trials, entry of start-ups & small biopharma in drug discovery, and increasing expenditure, and R&D by big biopharma companies are some of the factors driving the market growth.

Download Free Sample

The global clinical trials software market was valued at USD 930.22 million in 2021 and is anticipated to grow at a CAGR of 15.35% to reach USD 2.1 billion by 2027.

The key industry trends driving the global market growth are:

  • Cloud Computing in Clinical Trials
  • Entry of Start-ups & Small Biopharma in Drug Discovery
  • Increasing Expenditure and R&D by Big Biopharma Companies

Base Year: 2021

Forecast Year: 2022–2027

The study considers the global market's present scenario and dynamics for 2022−2027. It covers a detailed overview of several growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market. 

Key Vendors

  • BSI Business Systems Integration
    • Business Overview
    • Product Offerings
    • Key Strategies
    • Key Strengths
    • Key Opportunites
  • Clario
  • Dassault Systemes
  • IQVIA
  • Labcorp Drug Development
  • Oracle
  • Paraxel

Other Prominent Vendors are

  • Advarra
    • Business Overview
    • Product Offerings
  • ArisGlobal
  • AstraCOre
  • Axiom Real-time Metirics
  • Castor EDC
  • ClinCapture
  • DataTrial
  • DataTrak
  • IBM
  • Florence Healthcare
  • Fortress Medical
  • Medrio
  • Reify Health
  • Signant Health
  • SofPromed
  • Statsols
  • Veeva Systems (20)

Market Segments

Deployment

  • On-enterprises
  • On-Site

Delivery

  • Web-based
  • SaaS
  • On-Premises

Feature

  • EDC
  • eCOA/ePRO
  • eConsent

End-User

  • CROs
  • Bio-Pharmaceutical Companies
  • Medical Device Manufacturer
  • Others

Geography

North America

  • US
  • Canada

Europe

  • UK
  • France
  • Germany
  • Italy
  • Spain

Asia Pacific(APAC)

  • Japan
  • China
  • India
  • South Korea
  • Australia

Latin America

  • Brazil
  • Mexico
  • Argentina

Middle East & Africa

  • Turkey
  • Saudi Arabia
  • UAE
  • South Africa

1 RESEARCH METHODOLOGY
2 RESEARCH OBJECTIVES
3 RESEARCH PROCESS

4 SCOPE & COVERAGE

4.1 MARKET DEFINITION
4.1.1 INCLUSIONS
4.1.2 EXCLUSIONS
4.1.3 MARKET ESTIMATION CAVEATS
4.2 BASE YEAR
4.3 SCOPE OF THE STUDY
4.3.1 MARKET SEGMENTATION BY DEPLOYMENT
4.3.2 MARKET SEGMENTATION BY DELIVERY
4.3.3 MARKET SEGMENTATION BY FEATURE
4.3.4 MARKET SEGMENTATION BY END-USER
4.3.5 MARKET SEGMENTATION BY GEOGRAPHY

5 REPORT ASSUMPTIONS & CAVEATS
5.1 KEY CAVEATS
5.2 CURRENCY CONVERSION
5.3 MARKET DERIVATION

6 MARKET AT A GLANCE
7 INTRODUCTION

7.1 OVERVIEW
7.1.1 DEMAND FOR ADVANCED SOFTWARE

8 PREMIUM INSIGHTS
8.1 OVERVIEW

9 MARKET OPPORTUNITIES & TRENDS
9.1 NEW TECHNOLOGIES IN CLINICAL TRIALS
9.2 INCREASED VIRTUAL CLINICAL TRIALS
9.3 UNIFIED CLINICAL TRIAL PLATFORMS FOR NEXT-GENERATION CLINICAL TRIALS

10 MARKET GROWTH ENABLERS
10.1 CLOUD COMPUTING IN CLINICAL TRIALS
10.2 ADVENT OF DRUG DISCOVERY START-UPS & SMALL BIOPHARMA COMPANIES
10.3 INCREASED EXPENDITURE & R&D BY BIOPHARMA COMPANIES

11 MARKET RESTRAINTS
11.1 STRINGENT REGULATORY GUIDELINES RELATED TO DATA HANDLING
11.2 DATA SECURITY RISKS
11.3 USE OF TRADITIONAL CLINICAL TRIAL METHODS

12 MARKET LANDSCAPE
12.1 MARKET OVERVIEW
12.2 MARKET SIZE & FORECAST
12.3 FIVE FORCES ANALYSIS
12.3.1 THREAT OF NEW ENTRANTS
12.3.2 BARGAINING POWER OF SUPPLIERS
12.3.3 BARGAINING POWER OF BUYERS
12.3.4 THREAT OF SUBSTITUTES
12.3.5 COMPETITIVE RIVALRY

13 DEPLOYMENT
13.1 MARKET SNAPSHOT & GROWTH ENGINE
13.2 MARKET OVERVIEW
13.3 ON-ENTERPRISE
13.3.1 MARKET OVERVIEW
13.3.2 MARKET SIZE & FORECAST
13.3.3 MARKET BY GEOGRAPHY
13.4 ON-SITE
13.4.1 MARKET OVERVIEW
13.4.2 MARKET SIZE & FORECAST
13.4.3 MARKET BY GEOGRAPHY

14 DELIVERY
14.1 MARKET SNAPSHOT & GROWTH ENGINE
14.2 MARKET OVERVIEW
14.3 WEB-BASED
14.3.1 MARKET OVERVIEW
14.3.2 MARKET SIZE & FORECAST
14.3.3 MARKET BY GEOGRAPHY
14.4 SAAS
14.4.1 MARKET OVERVIEW
14.4.2 MARKET SIZE & FORECAST
14.4.3 MARKET BY GEOGRAPHY
14.5 ON-PREMISE
14.5.1 MARKET OVERVIEW
14.5.2 MARKET SIZE & FORECAST
14.5.3 MARKET BY GEOGRAPHY

15 FEATURE
15.1 MARKET SNAPSHOT & GROWTH ENGINE
15.2 MARKET OVERVIEW
15.3 EDC
15.3.1 MARKET OVERVIEW
15.3.2 MARKET SIZE & FORECAST
15.3.3 MARKET BY GEOGRAPHY
15.4 ECOA & EPRO
15.4.1 MARKET OVERVIEW
15.4.2 MARKET SIZE & FORECAST
15.4.3 MARKET BY GEOGRAPHY
15.5 ECONSENT
15.5.1 MARKET OVERVIEW
15.5.2 MARKET SIZE & FORECAST
15.5.3 MARKET BY GEOGRAPHY

16 END-USER
16.1 MARKET SNAPSHOT & GROWTH ENGINE
16.2 MARKET OVERVIEW
16.3 CROS
16.3.1 MARKET OVERVIEW
16.3.2 MARKET SIZE & FORECAST
16.3.3 MARKET BY GEOGRAPHY
16.4 BIOTECH & PHARMACEUTICAL COMPANIES
16.4.1 MARKET OVERVIEW
16.4.2 MARKET SIZE & FORECAST
16.4.3 MARKET BY GEOGRAPHY
16.5 MEDICAL DEVICE MANUFACTURERS
16.5.1 MARKET OVERVIEW
16.5.2 MARKET SIZE & FORECAST
16.5.3 MARKET BY GEOGRAPHY
16.6 OTHERS
16.6.1 MARKET OVERVIEW
16.6.2 MARKET SIZE & FORECAST
16.6.3 MARKET BY GEOGRAPHY

17 GEOGRAPHY
17.1 MARKET SNAPSHOT & GROWTH ENGINE
17.2 GEOGRAPHIC OVERVIEW

18 NORTH AMERICA
18.1 MARKET OVERVIEW
18.2 MARKET SIZE & FORECAST
18.3 DEPLOYMENT
18.3.1 MARKET SIZE & FORECAST
18.4 DELIVERY
18.4.1 MARKET SIZE & FORECAST
18.5 FEATURE
18.5.1 MARKET SIZE & FORECAST
18.6 END-USER
18.6.1 MARKET SIZE & FORECAST
18.7 KEY COUNTRIES
18.7.1 US: MARKET SIZE & FORECAST
18.7.2 CANADA: MARKET SIZE & FORECAST

19 EUROPE
19.1 MARKET OVERVIEW
19.2 MARKET SIZE & FORECAST
19.3 DEPLOYMENT
19.3.1 MARKET SIZE & FORECAST
19.4 DELIVERY
19.4.1 MARKET SIZE & FORECAST
19.5 FEATURE
19.5.1 MARKET SIZE & FORECAST
19.6 END-USER
19.6.1 MARKET SIZE & FORECAST
19.7 KEY COUNTRIES
19.7.1 GERMANY: MARKET SIZE & FORECAST
19.7.2 UK: MARKET SIZE & FORECAST
19.7.3 FRANCE: MARKET SIZE & FORECAST
19.7.4 SPAIN: MARKET SIZE & FORECAST
19.7.5 ITALY: MARKET SIZE & FORECAST

20 APAC
20.1 MARKET OVERVIEW
20.2 MARKET SIZE & FORECAST
20.3 DEPLOYMENT
20.3.1 MARKET SIZE & FORECAST
20.4 DELIVERY
20.4.1 MARKET SIZE & FORECAST
20.5 FEATURE
20.5.1 MARKET SIZE & FORECAST
20.6 END-USER
20.6.1 MARKET SIZE & FORECAST
20.7 KEY COUNTRIES
20.7.1 CHINA: MARKET SIZE & FORECAST
20.7.2 JAPAN: MARKET SIZE & FORECAST
20.7.3 INDIA: MARKET SIZE & FORECAST
20.7.4 SOUTH KOREA: MARKET SIZE & FORECAST
20.7.5 AUSTRALIA: MARKET SIZE & FORECAST

21 LATIN AMERICA
21.1 MARKET OVERVIEW
21.2 MARKET SIZE & FORECAST
21.3 DEPLOYMENT
21.3.1 MARKET SIZE & FORECAST
21.4 DELIVERY
21.4.1 MARKET SIZE & FORECAST
21.5 FEATURE
21.5.1 MARKET SIZE & FORECAST
21.6 END-USER
21.6.1 MARKET SIZE & FORECAST
21.7 KEY COUNTRIES
21.7.1 BRAZIL: MARKET SIZE & FORECAST
21.7.2 MEXICO: MARKET SIZE & FORECAST
21.7.3 ARGENTINA: MARKET SIZE & FORECAST

22 MIDDLE EAST & AFRICA
22.1 MARKET OVERVIEW
22.2 MARKET SIZE & FORECAST
22.3 DEPLOYMENT
22.3.1 MARKET SIZE & FORECAST
22.4 DELIVERY
22.4.1 MARKET SIZE & FORECAST
22.5 FEATURE
22.5.1 MARKET SIZE & FORECAST
22.6 END-USER
22.6.1 MARKET SIZE & FORECAST
22.7 KEY COUNTRIES
22.7.1 TURKEY: MARKET SIZE & FORECAST
22.7.2 SOUTH AFRICA: MARKET SIZE & FORECAST
22.7.3 SAUDI ARABIA: MARKET SIZE & FORECAST

23 COMPETITIVE LANDSCAPE
23.1 COMPETITION OVERVIEW
23.2 MARKET SHARE ANALYSIS
23.2.1 BSI BUSINESS SYSTEMS INTEGRATION AG
23.2.2 CLARIO
23.2.3 DASSAULT SYSTÈMES
23.2.4 IQVIA
23.2.5 LABCORP DRUG DEVELOPMENT
23.2.6 ORACLE CORPORATION
23.2.7 PAREXEL INTERNATIONAL CORPORATION

24 KEY COMPANY PROFILES
24.1 BSI BUSINESS SYSTEMS INTEGRATION AG
24.1.1 BUSINESS OVERVIEW
24.1.2 PRODUCT OFFERINGS
24.1.3 KEY STRATEGIES
24.1.4 KEY STRENGTHS
24.1.5 KEY OPPORTUNITIES
24.2 CLARIO
24.2.1 BUSINESS OVERVIEW
24.2.2 PRODUCT OFFERINGS
24.2.3 KEY STRATEGIES
24.2.4 KEY STRENGTHS
24.2.5 KEY OPPORTUNITIES
24.3 DASSAULT SYSTÈMES
24.3.1 BUSINESS OVERVIEW
24.3.2 PRODUCT OFFERINGS
24.3.3 KEY STRATEGIES
24.3.4 KEY STRENGTHS
24.3.5 KEY OPPORTUNITY
24.4 IQVIA
24.4.1 BUSINESS OVERVIEW
24.4.2 PRODUCT OFFERINGS
24.4.3 KEY STRATEGIES
24.4.4 KEY STRENGTHS
24.4.5 KEY OPPORTUNITIES
24.5 LABCORP DRUG DEVELOPMENT
24.5.1 BUSINESS OVERVIEW
24.5.2 PRODUCT OFFERINGS
24.5.3 KEY STRATEGIES
24.5.4 KEY STRENGTHS
24.5.5 KEY OPPORTUNITIES
24.6 ORACLE CORPORATION
24.6.1 BUSINESS OVERVIEW
24.6.2 PRODUCT OFFERINGS
24.6.3 KEY STRATEGIES
24.6.4 KEY STRENGTHS
24.6.5 KEY OPPORTUNITIES
24.7 PARAXEL INTERNATIONAL CORPORATION
24.7.1 BUSINESS OVERVIEW
24.7.2 PRODUCT OFFERINGS
24.7.3 KEY STRATEGIES
24.7.4 KEY STRENGTHS
24.7.5 KEY OPPORTUNITIES

25 OTHER PROMINENT VENDORS
25.1 ADVARRA
25.1.1 BUSINESS OVERVIEW
25.1.2 PRODUCT OFFERINGS
25.2 ARISGLOBAL
25.2.1 BUSINESS OVERVIEW
25.2.2 PRODUCT OFFERINGS
25.3 ASTRACORE
25.3.1 BUSINESS OVERVIEW
25.3.2 PRODUCT OFFERINGS
25.4 AXIOM REAL-TIME METRICS
25.4.1 BUSINESS OVERVIEW
25.4.2 PRODUCT OFFERINGS
25.5 CASTOR EDC
25.5.1 BUSINESS OVERVIEW
25.5.2 PRODUCT OFFERINGS
25.6 CLINCAPTURE
25.6.1 BUSINESS OVERVIEW
25.6.2 PRODUCT OFFERINGS
25.7 DATATRIAL
25.7.1 BUSINESS OVERVIEW
25.7.2 PRODUCT OFFERINGS
25.8 DATATRAK INT.
25.8.1 BUSINESS OVERVIEW
25.8.2 PRODUCT OFFERINGS
25.9 IBM
25.9.1 BUSINESS OVERVIEW
25.9.2 PRODUCT OFFERINGS
25.10 FLORENCE HEALTHCARE
25.10.1 BUSINESS OVERVIEW
25.10.2 PRODUCT OFFERINGS
25.11 FORTRESS MEDICAL
25.11.1 BUSINESS OVERVIEW
25.11.2 PRODUCT OFFERINGS
25.12 MEDRIO
25.12.1 BUSINESS OVERVIEW
25.12.2 PRODUCT OFFERINGS
25.13 OPENCLINICA, LLC
25.13.1 BUSINESS OVERVIEW
25.13.2 PRODUCT OFFERINGS
25.14 REALTIME SOFTWARE SOLUTIONS
25.14.1 BUSINESS OVERVIEW
25.14.2 PRODUCT OFFERINGS
25.15 RESEARCH MANAGER
25.15.1 BUSINESS OVERVIEW
25.15.2 PRODUCT OFFERINGS
25.16 REIFY HEALTH, INC.
25.16.1 BUSINESS OVERVIEW
25.16.2 PRODUCT OFFERINGS
25.17 SIGNANT HEALTH
25.17.1 BUSINESS OVERVIEW
25.17.2 PRODUCT OFFERINGS
25.18 SOFPROMED
25.18.1 BUSINESS OVERVIEW
25.18.2 PRODUCT OFFERINGS
25.19 STATSOLS
25.19.1 BUSINESS OVERVIEW
25.19.2 PRODUCT OFFERINGS
25.20 VEEVA SYSTEMS
25.20.1 BUSINESS OVERVIEW
25.20.2 PRODUCT OFFERINGS

26 REPORT SUMMARY
26.1 KEY TAKEAWAYS
26.2 STRATEGIC RECOMMENDATIONS

27 QUANTITATIVE SUMMARY
27.1 GEOGRAPHY
27.2 DEPLOYMENT
27.3 DELIVERY
27.4 FEATURE
27.5 END-USER
27.6 DEPLOYMENT: GEOGRAPHY INSIGHTS
27.6.1 ON-ENTERPRISE: GEOGRAPHY INSIGHTS
27.6.2 ON-SITE: GEOGRAPHY INSIGHTS
27.7 DELIVERY: GEOGRAPHY INSIGHTS
27.7.1 WEB-BASED: GEOGRAPHY INSIGHTS
27.7.2 SAAS: GEOGRAPHY INSIGHTS
27.7.3 ON-PREMISE: GEOGRAPHY INSIGHTS
27.8 FEATURE: GEOGRAPHY INSIGHTS
27.8.1 EDC: GEOGRAPHY INSIGHTS
27.8.2 ECOA & EPRO: GEOGRAPHY INSIGHTS
27.8.3 ECONSENT: GEOGRAPHY INSIGHTS
27.9 END-USER: GEOGRAPHY INSIGHTS
27.9.1 CROS: GEOGRAPHY INSIGHTS
27.9.2 BIOTECH & PHARMACEUTICAL COMPANIES: GEOGRAPHY INSIGHTS
27.9.3 MEDICAL DEVICE MANUFACTURERS: GEOGRAPHY INSIGHTS
27.9.4 OTHERS: GEOGRAPHY INSIGHTS

28 APPENDIX
28.1 ABBREVIATIONS

EXHIBIT 1 SEGMENTATION OF GLOBAL CLINICAL TRIAL SOFTWARE MARKET
EXHIBIT 2 MARKET SIZE CALCULATION APPROACH 2021
EXHIBIT 3 TOTAL NUMBER OF CLINICAL TRIALS CONDUCTED GLOBALLY BETWEEN 2000 AND 2020
EXHIBIT 4 CLINICAL TRIALS BY COUNTRIES UNTIL 2022
EXHIBIT 5 TOTAL NUMBER OF CLINICAL TRIALS CONDUCTED GLOBALLY (2000–2021)
EXHIBIT 6 NUMBER OF MEDICINES IN DEVELOPMENT GLOBALLY IN 2020 BASED ON THERAPEUTIC AREA
EXHIBIT 7 CLOUD COMPUTING BENEFITS IN CLINICAL TRIAL SOFTWARE SEGMENT
EXHIBIT 8 IMPACT OF NEW TECHNOLOGIES IN CLINICAL TRIALS
EXHIBIT 9 ADOPTION OF NEW TECHNOLOGIES IN CLINICAL TRIALS 2020–2022
EXHIBIT 10 BENEFITS OF REMOTE MONITORING OF CLINICAL TRIALS
EXHIBIT 11 IMPACT OF INCREASED VIRTUAL CLINICAL TRIALS
EXHIBIT 12 FEATURES & ADVANTAGES OF VIRTUAL CLINICAL TRIALS
EXHIBIT 13 IMPACT OF UNIFIED CLINICAL TRIAL PLATFORMS FOR NEXT-GENERATION CLINICAL TRIALS
EXHIBIT 14 IMPACT OF CLOUD COMPUTING IN CLINICAL TRIALS
EXHIBIT 15 BENEFITS OF CLOUD COMPUTING IN CLINICAL TRIALS
EXHIBIT 16 IMPACT OF ADVENT OF DRUG DISCOVERY START-UPS & SMALL BIOPHARMA COMPANIES
EXHIBIT 17 GLOBAL NEW DRUG APPROVALS BY VARIOUS SIZE PHARMA & BIO-PHARMA COMPANIES 2009–2018
EXHIBIT 18 IMPACT OF INCREASED EXPENDITURE & R&D BY BIOPHARMA COMPANIES
EXHIBIT 19 EXPENDITURE & DRUG DISCOVERY DEVELOPMENT BY TOP PHARMACEUTICAL COMPANIES GLOBALLY (1980–2021)
EXHIBIT 20 TOP 20 R&D SPENDERS RANKED BY SPENDING AS A PERCENT OF REVENUE
EXHIBIT 21 IMPACT OF STRINGENT REGULATORY GUIDELINES RELATED TO DATA HANDLING
EXHIBIT 22 TOP OPERATIONAL CHALLENGES RELATED TO CLINICAL TRIAL DATA 2018
EXHIBIT 23 GLOBAL ACCESS TO REAL-TIME CLINICAL TRIAL DATA 2018
EXHIBIT 24 IMPACT OF DATA SECURITY RISKS
EXHIBIT 25 IMPACT OF USE OF TRADITIONAL CLINICAL TRIAL METHODS
EXHIBIT 26 CLINICAL TRIALS ACTIVITIES BY TRADITIONAL, HYBRID & DECENTRALIZED – 2021
EXHIBIT 27 GLOBAL CLINICAL TRIAL SOFTWARE MARKET 2021–2027 ($ MILLION)
EXHIBIT 28 FIVE FORCES ANALYSIS 2021
EXHIBIT 29 INCREMENTAL GROWTH BY DEPLOYMENT 2021 & 2027
EXHIBIT 30 GLOBAL CLINICAL TRIAL SOFTWARE MARKET BY DEPLOYMENT 2021–2027
EXHIBIT 31 GLOBAL CLINICAL TRIAL SOFTWARE MARKET BY DEPLOYMENT: OVERVIEW
EXHIBIT 32 GLOBAL CLINICAL TRIAL SOFTWARE MARKET BY DEPLOYMENT: INCREMENTAL GROWTH
EXHIBIT 33 GLOBAL CLINICAL TRIAL SOFTWARE MARKET BY DEPLOYMENT: ABSOLUTE GROWTH
EXHIBIT 34 GLOBAL CLINICAL TRIAL SOFTWARE MARKET BY ON-ENTERPRISE DEPLOYMENT: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 35 GLOBAL ON-ENTERPRISE DEPLOYMENT CLINICAL TRIAL SOFTWARE MARKET 2021–2027 ($ MILLION)
EXHIBIT 36 GLOBAL CLINICAL TRIAL SOFTWARE MARKET BY ON-SITE DEPLOYMENT: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 37 GLOBAL ON-SITE DEPLOYMENT CLINICAL TRIAL SOFTWARE MARKET 2021–2027 ($ MILLION)
EXHIBIT 38 INCREMENTAL GROWTH BY DELIVERY 2021 & 2027
EXHIBIT 39 GLOBAL CLINICAL TRIAL SOFTWARE MARKET BY DELIVERY 2021–2027
EXHIBIT 40 GLOBAL CLINICAL TRIAL SOFTWARE MARKET BY DELIVERY: OVERVIEW
EXHIBIT 41 GLOBAL CLINICAL TRIAL SOFTWARE MARKET BY DELIVERY: INCREMENTAL GROWTH
EXHIBIT 42 GLOBAL CLINICAL TRIAL SOFTWARE MARKET BY DELIVERY: ABSOLUTE GROWTH
EXHIBIT 43 GLOBAL CLINICAL TRIAL SOFTWARE MARKET BY WEB-BASED DELIVERY: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 44 GLOBAL WEB-BASED DELIVERY CLINICAL TRIAL SOFTWARE MARKET 2021–2027 ($ MILLION)
EXHIBIT 45 GLOBAL CLINICAL TRIAL SOFTWARE MARKET BY SAAS DELIVERY: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 46 GLOBAL SAAS DELIVERY CLINICAL TRIAL SOFTWARE MARKET 2021–2027 ($ MILLION)
EXHIBIT 47 GLOBAL CLINICAL TRIAL SOFTWARE MARKET BY ON-PREMISE DELIVERY: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 48 GLOBAL ON-PREMISE DELIVERY CLINICAL TRIAL SOFTWARE MARKET 2021–2027 ($ MILLION)
EXHIBIT 49 INCREMENTAL GROWTH BY FEATURE 2021 & 2027
EXHIBIT 50 GLOBAL CLINICAL TRIAL SOFTWARE MARKET BY FEATURE 2021–2027
EXHIBIT 51 GLOBAL CLINICAL TRIAL SOFTWARE MARKET BY FEATURE: OVERVIEW
EXHIBIT 52 GLOBAL CLINICAL TRIAL SOFTWARE MARKET BY FEATURE: INCREMENTAL GROWTH
EXHIBIT 53 GLOBAL CLINICAL TRIAL SOFTWARE MARKET BY FEATURE: ABSOLUTE GROWTH
EXHIBIT 54 EDC: ADVANTAGES IN CLINICAL TRIALS
EXHIBIT 55 GLOBAL CLINICAL TRIAL SOFTWARE MARKET BY EDC FEATURE: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 56 GLOBAL EDC FEATURE CLINICAL TRIAL SOFTWARE MARKET 2021–2027 ($ MILLION)
EXHIBIT 57 GLOBAL CLINICAL TRIAL SOFTWARE MARKET BY ECOA & EPRO FEATURE: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 58 GLOBAL ECOA/EPRO FEATURE CLINICAL TRIAL SOFTWARE MARKET 2021–2027 ($ MILLION)
EXHIBIT 59 GLOBAL CLINICAL TRIAL SOFTWARE MARKET BY ECONSENT FEATURE: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 60 GLOBAL ECONSENT FEATURE CLINICAL TRIAL SOFTWARE MARKET 2021–2027 ($ MILLION)
EXHIBIT 61 INCREMENTAL GROWTH BY END-USER 2021 & 2027
EXHIBIT 62 GLOBAL CLINICAL TRIAL SOFTWARE MARKET BY END-USER 2021–2027
EXHIBIT 63 GLOBAL CLINICAL TRIAL SOFTWARE MARKET BY END-USER: OVERVIEW
EXHIBIT 64 GLOBAL CLINICAL TRIAL SOFTWARE MARKET BY END-USER: GROWTH IMPACT
EXHIBIT 65 GLOBAL CLINICAL TRIAL SOFTWARE MARKET BY END-USER: INCREMENTAL GROWTH
EXHIBIT 66 GLOBAL CLINICAL TRIAL SOFTWARE MARKET BY END-USER: ABSOLUTE GROWTH
EXHIBIT 67 GLOBAL CLINICAL TRIAL SOFTWARE MARKET BY CROS: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 68 GLOBAL CROS CLINICAL TRIAL SOFTWARE MARKET 2021–2027 ($ MILLION)
EXHIBIT 69 CLINICAL TRIAL SOFTWARE MARKET BY BIOTECH & PHARMACEUTICAL COMPANIES: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 70 GLOBAL BIOTECH & PHARMACEUTICAL COMPANIES CLINICAL TRIAL SOFTWARE MARKET 2021–2027 ($ MILLION)
EXHIBIT 71 GLOBAL CLINICAL TRIAL SOFTWARE MARKET BY MEDICAL DEVICE MANUFACTURERS: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 72 GLOBAL MEDICAL DEVICE MANUFACTURERS CLINICAL TRIAL SOFTWARE MARKET 2021–2027 ($ MILLION)
EXHIBIT 73 GLOBAL CLINICAL TRIAL SOFTWARE MARKET BY OTHERS: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 74 GLOBAL OTHERS CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 ($ MILLION)
EXHIBIT 75 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 76 GLOBAL CLINICAL TRIAL SOFTWARE MARKET BY REGION 2021-2027
EXHIBIT 77 GLOBAL CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY: INCREMENTAL GROWTH
EXHIBIT 78 GLOBAL CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY: ABSOLUTE GROWTH
EXHIBIT 79 NORTH AMERICA CLINICAL TRIAL SOFTWARE MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 80 NUMBER OF CLINICAL TRIALS IN NORTH AMERICA 2000–2021
EXHIBIT 81 NORTH AMERICA CLINICAL TRIAL SOFTWARE MARKET: KEY COUNTRIES
EXHIBIT 82 NORTH AMERICA CLINICAL TRIAL SOFTWARE MARKET 2021–2027 ($ MILLION)
EXHIBIT 83 INCREMENTAL GROWTH IN NORTH AMERICA 2021 & 2027
EXHIBIT 84 US CLINICAL TRIAL SOFTWARE MARKET 2021–2027 ($ MILLION)
EXHIBIT 85 CANADA CLINICAL TRIAL SOFTWARE MARKET 2021–2027 ($ MILLION)
EXHIBIT 86 EUROPE CLINICAL TRIAL SOFTWARE MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 87 EUROPE CLINICAL TRIAL SOFTWARE MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 88 EUROPE CLINICAL TRIAL SOFTWARE MARKET: KEY COUNTRIES
EXHIBIT 89 TOTAL NUMBER OF CLINICAL TRIAL STUDIES REGISTERED IN EUROPE 2013–2021
EXHIBIT 90 EUROPE CLINICAL TRIAL SOFTWARE MARKET 2021–2027 ($ MILLION)
EXHIBIT 91 INCREMENTAL GROWTH IN EUROPE 2021 & 2027
EXHIBIT 92 GERMANY CLINICAL TRIAL SOFTWARE MARKET 2021–2027 ($ MILLION)
EXHIBIT 93 UK: FUNDING ORGANIZATIONS FOR CLINICAL TRIALS 2021
EXHIBIT 94 UK CLINICAL TRIAL SOFTWARE MARKET 2021–2027 ($ MILLION)
EXHIBIT 95 FRANCE CLINICAL TRIAL SOFTWARE MARKET 2021–2027 ($ MILLION)
EXHIBIT 96 SPAIN CLINICAL TRIAL SOFTWARE MARKET 2021–2027 ($ MILLION)
EXHIBIT 97 ITALY CLINICAL TRIAL SOFTWARE MARKET 2021–2027 ($ MILLION)
EXHIBIT 98 APAC CLINICAL TRIAL SOFTWARE MARKET: KEY COUNTRIES
EXHIBIT 99 CROS IN APAC COUNTRIES
EXHIBIT 100 APAC CLINICAL TRIAL SOFTWARE MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 101 APAC CLINICAL TRIAL SOFTWARE MARKET 2021–2027 ($ MILLION)
EXHIBIT 102 INCREMENTAL GROWTH IN APAC 2021 & 2027
EXHIBIT 103 CHINA: CLINICAL TRIALS 2012–2021 (TEN YEAR TREND)
EXHIBIT 104 CHINA CLINICAL TRIAL SOFTWARE MARKET 2021–2027 ($ MILLION)
EXHIBIT 105 JAPAN CLINICAL TRIAL SOFTWARE MARKET 2021–2027 ($ MILLION)
EXHIBIT 106 PERCENTAGE INCREASE IN CLINICAL TRIALS IN INDIA 2011–2020 (%)
EXHIBIT 107 VIRTUAL TRIALS CONDUCTED IN INDIA 2014–2022
EXHIBIT 108 INDIA CLINICAL TRIAL SOFTWARE MARKET 2021–2027 ($ MILLION)
EXHIBIT 109 SOUTH KOREA CLINICAL TRIAL SOFTWARE MARKET 2021–2027 ($ MILLION)
EXHIBIT 110 AUSTRALIA CLINICAL TRIAL SOFTWARE MARKET 2021–2027 ($ MILLION)
EXHIBIT 111 LATIN AMERICA CLINICAL TRIAL SOFTWARE MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 112 LATIN AMERICA CLINICAL TRIAL SOFTWARE MARKET: KEY COUNTRIES
EXHIBIT 113 LATIN AMERICA CLINICAL TRIAL SOFTWARE MARKET 2021–2027 ($ MILLION)
EXHIBIT 114 INCREMENTAL GROWTH IN LATIN AMERICA 2021 & 2027
EXHIBIT 115 BRAZIL CLINICAL TRIAL SOFTWARE MARKET 2021–2027 ($ MILLION)
EXHIBIT 116 MEXICO CLINICAL TRIAL SOFTWARE MARKET 2021–2027 ($ MILLION)
EXHIBIT 117 ARGENTINA CLINICAL TRIAL SOFTWARE MARKET 2021–2027 ($ MILLION)
EXHIBIT 118 MIDDLE EAST & AFRICA CLINICAL TRIAL SOFTWARE MARKET: KEY COUNTRIES
EXHIBIT 119 MIDDLE EAST & AFRICA CLINICAL TRIAL SOFTWARE MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 120 MIDDLE EAST & AFRICA CLINICAL TRIAL SOFTWARE MARKET 2021–2027 ($ MILLION)
EXHIBIT 121 INCREMENTAL GROWTH IN MIDDLE EAST & AFRICA 2021 & 2027
EXHIBIT 122 TURKEY: CLINICAL TRIAL SOFTWARE MARKET DRIVERS
EXHIBIT 123 TURKEY CLINICAL TRIAL SOFTWARE MARKET 2021–2027 ($ MILLION)
EXHIBIT 124 SOUTH AFRICA CLINICAL TRIAL SOFTWARE MARKET 2021–2027 ($ MILLION)
EXHIBIT 125 SAUDI ARABIA CLINICAL TRIAL SOFTWARE MARKET 2021–2027 ($ MILLION)
EXHIBIT 126 PURE & DIVERSIFIED VENDORS IN GLOBAL CLINICAL TRIAL SOFTWARE MARKET
EXHIBIT 127 CLINICAL TRIAL SOFTWARE VENDORS: MARKET DOMINANCE ANALYSIS
EXHIBIT 128 VENDORS OFFERING CLINICAL TRIAL SOFTWARE: CAPABILITIES & EXPERTISE ASSESSMENT
EXHIBIT 129 IQVIA: ANNUAL REVENUE 2019–2021 ($ MILLION)
EXHIBIT 130 LABCORP DRUG DEVELOPMENT: ANNUAL REVENUE 2019–2021 ($ MILLION)
EXHIBIT 131 ORACLE CORPORATION: ANNUAL REVENUE 2019–2021 ($ MILLION)
EXHIBIT 132 ORACLE CORPORATION: REVENUE BY GEOGRAPHY 2021 ($ MILLION)
EXHIBIT 133 ORACLE CORPORATION: REVENUE BY CLOUD-BASED SEGMENT 2021 ($ MILLION)

LIST OF TABLES

TABLE 1 KEY CAVEATS
TABLE 2 CURRENCY CONVERSION 2015−2021
TABLE 3 ON-ENTERPRISE DEPLOYMENT CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 ($ MILLION)
TABLE 4 ON-ENTERPRISE DEPLOYMENT CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 (%)
TABLE 5 ON-SITE DEPLOYMENT CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 ($ MILLION)
TABLE 6 ON-SITE DEPLOYMENT CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 (%)
TABLE 7 WEB-BASED DELIVERY CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 ($ MILLION)
TABLE 8 WEB-BASED DELIVERY CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 (%)
TABLE 9 SAAS DELIVERY CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 ($ MILLION)
TABLE 10 SAAS DELIVERY CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 (%)
TABLE 11 ON-PREMISE DELIVERY CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 ($ MILLION)
TABLE 12 ON-PREMISE DELIVERY CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 (%)
TABLE 13 SOME KNOWN EDC CLINICAL TRIAL SOFTWARE IN 2022
TABLE 14 EDC FEATURE CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 ($ MILLION)
TABLE 15 EDC FEATURE CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 (%)
TABLE 16 SOME KNOWN ECOA & EPRO SYSTEMS IN 2022
TABLE 17 ECOA/EPRO FEATURE CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 ($ MILLION)
TABLE 18 ECOA/EPRO FEATURE CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 (%)
TABLE 19 ECONSENT FEATURE CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 ($ MILLION)
TABLE 20 ECONSENT FEATURE CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 (%)
TABLE 21 CROS CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 ($ MILLION)
TABLE 22 CROS CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 (%)
TABLE 23 BIOTECH & PHARMACEUTICAL COMPANIES MARKET BY GEOGRAPHY 2021–2027 ($ MILLION)
TABLE 24 BIOTECH & PHARMACEUTICAL COMPANIES MARKET BY GEOGRAPHY 2021–2027 (%)
TABLE 25 MEDICAL DEVICE MANUFACTURERS CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 ($ MILLION)
TABLE 26 MEDICAL DEVICE MANUFACTURERS CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 (%)
TABLE 27 OTHERS CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 ($ MILLION)
TABLE 28 OTHERS CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 (%)
TABLE 29 NORTH AMERICA CLINICAL TRIAL SOFTWARE MARKET BY DEPLOYMENT 2021–2027 ($ MILLION)
TABLE 30 NORTH AMERICA CLINICAL TRIAL SOFTWARE MARKET BY DEPLOYMENT 2021–2027 (%)
TABLE 31 NORTH AMERICA CLINICAL TRIAL SOFTWARE MARKET BY DELIVERY 2021–2027 ($ MILLION)
TABLE 32 NORTH AMERICA CLINICAL TRIAL SOFTWARE MARKET BY DELIVERY 2021–2027 (%)
TABLE 33 NORTH AMERICA CLINICAL TRIAL SOFTWARE MARKET BY FEATURE 2021–2027 ($ MILLION)
TABLE 34 NORTH AMERICA CLINICAL TRIAL SOFTWARE MARKET BY FEATURE 2021–2027 (%)
TABLE 35 NORTH AMERICA CLINICAL TRIAL SOFTWARE MARKET BY END-USER 2021–2027 ($ MILLION)
TABLE 36 NORTH AMERICA CLINICAL TRIAL SOFTWARE MARKET BY END-USER 2021–2027 (%)
TABLE 37 KEY CLOUD-BASED CLINICAL TRIAL SOFTWARE USED IN CANADA 2022
TABLE 38 EUROPE CLINICAL TRIAL SOFTWARE MARKET BY DEPLOYMENT 2021–2027 ($ MILLION)
TABLE 39 EUROPE CLINICAL TRIAL SOFTWARE MARKET BY DEPLOYMENT 2021–2027 (%)
TABLE 40 EUROPE CLINICAL TRIAL SOFTWARE MARKET BY DELIVERY 2021–2027 ($ MILLION)
TABLE 41 EUROPE CLINICAL TRIAL SOFTWARE MARKET BY DELIVERY 2021–2027 (%)
TABLE 42 EUROPE CLINICAL TRIAL SOFTWARE MARKET BY FEATURE 2021–2027 ($ MILLION)
TABLE 43 EUROPE CLINICAL TRIAL SOFTWARE MARKET BY FEATURE 2021–2027 (%)
TABLE 44 EUROPE CLINICAL TRIAL SOFTWARE MARKET BY END-USER 2021–2027 ($ MILLION)
TABLE 45 EUROPE CLINICAL TRIAL SOFTWARE MARKET BY END-USER 2021–2027 (%)
TABLE 46 APAC CLINICAL TRIAL SOFTWARE MARKET BY DEPLOYMENT 2021–2027 ($ MILLION)
TABLE 47 APAC CLINICAL TRIAL SOFTWARE MARKET BY DEPLOYMENT 2021–2027 (%)
TABLE 48 APAC CLINICAL TRIAL SOFTWARE MARKET BY DELIVERY 2021–2027 ($ MILLION)
TABLE 49 APAC CLINICAL TRIAL SOFTWARE MARKET BY DELIVERY 2021–2027 (%)
TABLE 50 APAC CLINICAL TRIAL SOFTWARE MARKET BY FEATURE 2021–2027 ($ MILLION)
TABLE 51 APAC CLINICAL TRIAL SOFTWARE MARKET BY FEATURE 2021–2027 (%)
TABLE 52 APAC CLINICAL TRIAL SOFTWARE MARKET BY END-USER 2021–2027 ($ MILLION)
TABLE 53 APAC CLINICAL TRIAL SOFTWARE MARKET BY END-USER 2021–2027 (%)
TABLE 54 LATIN AMERICA CLINICAL TRIAL SOFTWARE MARKET BY DEPLOYMENT 2021–2027 ($ MILLION)
TABLE 55 LATIN AMERICA CLINICAL TRIAL SOFTWARE MARKET BY DEPLOYMENT 2021–2027 (%)
TABLE 56 LATIN AMERICA CLINICAL TRIAL SOFTWARE MARKET BY DELIVERY 2021–2027 ($ MILLION)
TABLE 57 LATIN AMERICA CLINICAL TRIAL SOFTWARE MARKET BY DELIVERY 2021–2027 (%)
TABLE 58 LATIN AMERICA CLINICAL TRIAL SOFTWARE MARKET BY FEATURE 2021–2027 ($ MILLION)
TABLE 59 LATIN AMERICA CLINICAL TRIAL SOFTWARE MARKET BY FEATURE 2021–2027 (%)
TABLE 60 LATIN AMERICA CLINICAL TRIAL SOFTWARE MARKET BY END-USER 2021–2027 ($ MILLION)
TABLE 61 LATIN AMERICA CLINICAL TRIAL SOFTWARE MARKET BY END-USER 2021–2027 (%)
TABLE 62 MIDDLE EAST & AFRICA CLINICAL TRIAL SOFTWARE MARKET BY DEPLOYMENT 2021–2027 ($ MILLION)
TABLE 63 MIDDLE EAST & AFRICA CLINICAL TRIAL SOFTWARE MARKET BY DEPLOYMENT 2021–2027 (%)
TABLE 64 MIDDLE EAST & AFRICA CLINICAL TRIAL SOFTWARE MARKET BY DELIVERY 2021–2027 ($ MILLION)
TABLE 65 MIDDLE EAST & AFRICA CLINICAL TRIAL SOFTWARE MARKET BY DELIVERY 2021–2027 (%)
TABLE 66 MIDDLE EAST & AFRICA CLINICAL TRIAL SOFTWARE MARKET BY FEATURE 2021–2027 ($ MILLION)
TABLE 67 MIDDLE EAST & AFRICA CLINICAL TRIAL SOFTWARE MARKET BY FEATURE 2021–2027 (%)
TABLE 68 MIDDLE EAST & AFRICA TRIAL SOFTWARE MARKET BY END-USER 2021–2027 ($ MILLION)
TABLE 69 MIDDLE EAST & AFRICA CLINICAL TRIAL SOFTWARE MARKET BY END-USER 2021–2027 (%)
TABLE 70 BSI BUSINESS SYSTEMS INTEGRATION AG: MAJOR PRODUCT OFFERINGS
TABLE 71 CLARIO: MAJOR PRODUCT OFFERINGS
TABLE 72 DASSAULT SYSTÈMES: MAJOR PRODUCT OFFERINGS
TABLE 73 IQVIA: MAJOR PRODUCT OFFERINGS
TABLE 74 LABCORP DRUG DEVELOPMENT: MAJOR PRODUCT OFFERINGS
TABLE 75 ORACLE CORPORATION: MAJOR PRODUCT OFFERINGS
TABLE 76 PARAXEL INTERNATIONAL CORPORATION: MAJOR PRODUCT OFFERINGS
TABLE 77 ADVARRA: MAJOR PRODUCT OFFERINGS
TABLE 78 ARISGLOBAL: MAJOR PRODUCT OFFERINGS
TABLE 79 ASTRACORE: MAJOR PRODUCT OFFERINGS
TABLE 80 AXIOM REAL-TIME METRICS: MAJOR PRODUCT OFFERINGS
TABLE 81 CASTOR EDC: MAJOR PRODUCT OFFERINGS
TABLE 82 CLINCAPTURE: MAJOR PRODUCT OFFERINGS
TABLE 83 DATATRIAL: MAJOR PRODUCT OFFERINGS
TABLE 84 DATATRAK INT.: MAJOR PRODUCT OFFERINGS
TABLE 85 IBM: MAJOR PRODUCT OFFERINGS
TABLE 86 FLORENCE HEALTHCARE: MAJOR PRODUCT OFFERINGS
TABLE 87 FORTRESS MEDICAL: MAJOR PRODUCT OFFERINGS
TABLE 88 MEDRIO: MAJOR PRODUCT OFFERINGS
TABLE 89 OPENCLINICA, LLC: MAJOR PRODUCT OFFERINGS
TABLE 90 REALTIME SOFTWARE SOLUTIONS: MAJOR PRODUCT OFFERINGS
TABLE 91 RESEARCHMANAGER: MAJOR PRODUCT OFFERINGS
TABLE 92 REIFY HEALTH, INC.: MAJOR PRODUCT OFFERINGS
TABLE 93 SIGNANT HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 94 SOFPROMED: MAJOR PRODUCT OFFERINGS
TABLE 95 STATSOLS: MAJOR PRODUCT OFFERINGS
TABLE 96 VEEVA SYSTEMS: MAJOR PRODUCT OFFERINGS
TABLE 97 GLOBAL CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 ($ MILLION)
TABLE 98 GLOBAL CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 (%)
TABLE 99 GLOBAL CLINICAL TRIAL SOFTWARE MARKET BY DEPLOYMENT 2021–2027 ($ MILLION)
TABLE 100 GLOBAL CLINICAL TRIAL SOFTWARE MARKET BY DEPLOYMENT 2021–2027 (%)
TABLE 101 GLOBAL CLINICAL TRIAL SOFTWARE MARKET BY DELIVERY 2021–2027 ($ MILLION)
TABLE 102 GLOBAL CLINICAL TRIAL SOFTWARE MARKET BY DELIVERY 2021–2027 (%)
TABLE 103 GLOBAL CLINICAL TRIAL SOFTWARE MARKET BY FEATURE 2021–2027 ($ MILLION)
TABLE 104 GLOBAL CLINICAL TRIAL SOFTWARE MARKET BY FEATURE 2021–2027 (%)
TABLE 105 GLOBAL CLINICAL TRIAL SOFTWARE MARKET BY END-USER 2021–2027 ($ MILLION)
TABLE 106 GLOBAL CLINICAL TRIAL SOFTWARE MARKET BY END-USER 2021–2027 (%)
TABLE 107 ON-ENTERPRISE CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 ($ MILLION)
TABLE 108 ON-ENTERPRISE CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 (%)
TABLE 109 ON-SITE CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 ($ MILLION)
TABLE 110 ON-SITE CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 (%)
TABLE 111 WEB-BASED CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 ($ MILLION)
TABLE 112 WEB-BASED CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 (%)
TABLE 113 SAAS CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 ($ MILLION)
TABLE 114 SAAS CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 (%)
TABLE 115 ON-PREMISE CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 ($ MILLION)
TABLE 116 ON-PREMISE CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 (%)
TABLE 117 EDC CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 ($ MILLION)
TABLE 118 EDC CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 (%)
TABLE 119 ECOA & EPRO CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 ($ MILLION)
TABLE 120 ECOA & EPRO CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 (%)
TABLE 121 ECONSENT CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 ($ MILLION)
TABLE 122 ECONSENT CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 (%)
TABLE 123 CROS CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 ($ MILLION)
TABLE 124 CROS CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 (%)
TABLE 125 BIOTECH & PHARMACEUTICAL COMPANIES CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 ($ MILLION)
TABLE 126 BIOTECH & PHARMACEUTICAL COMPANIES CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 (%)
TABLE 127 MEDICAL DEVICE MANUFACTURERS CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 ($ MILLION)
TABLE 128 MEDICAL DEVICE MANUFACTURERS CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 (%)
TABLE 129 OTHERS CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 ($ MILLION)
TABLE 130 OTHERS CLINICAL TRIAL SOFTWARE MARKET BY GEOGRAPHY 2021–2027 (%)

Select a license type that suits your business needs

single-user Single User Licence
$3500.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5-user 5 User Licence
$3995.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
corporate.png Corporate Licence
$4995.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
datasheet.png Datasheet Licence
$1500.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Our Clients

Licence Types What are these?

Interested in data center portfolio for this report?
Click here

Our Clients Speak

erick

"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios
SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Want to Customize the Report?

Click Here

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date